Abstract: The present invention relates to methods of diagnosing, predicting and monitoring kidney disorders. In particular, the present invention relates to the diagnosis, prediction and monitoring of kidney disorders by detection of cytokines, cytokine-related compounds and chemokines in urine. The present invention further relates to methods and compositions for assessing the efficacy of agents and interventions used to treat kidney disorders.

Abstract: The present invention relates to methods of diagnosing, predicting and monitoring kidney disorders. In particular, the present invention relates to the diagnosis, prediction and monitoring of kidney disorders by detection of cytokines, cytokine-related compounds and chemokines in urine. The present invention further relates to methods and compositions for assessing the efficacy of agents and interventions used to treat kidney disorders.

Abstract: The present invention relates to methods of diagnosing, predicting and monitoring kidney disorders. In particular, the present invention relates to the diagnosis, prediction and monitoring of kidney disorders by detection of cytokines, cytokine-related compounds and chemokines in urine. The present invention further relates to methods and compositions for assessing the efficacy of agents and interventions used to treat kidney disorders.

Abstract: The present invention provides systems and methods for characterizing biological markers in the urine of systemic lupus erythematosus (SLE) subjects. In particular, the present invention relates to the detection of cytokines and chemokines in urine of SLE subjects for determining nephritic disease states and kidney damage in SLE subjects and the efficacy of agents and interventions used to treat lupus nephritis.

Abstract: The present invention relates to methods of diagnosing, predicting and monitoring kidney disorders. In particular, the present invention relates to the diagnosis, prediction and monitoring of kidney disorders by detection of cytokines, cytokine-related compounds and chemokines in urine. The present invention further relates to methods and compositions for assessing the efficacy of agents and interventions used to treat kidney disorders.

Abstract: The present invention relates to methods of diagnosing and predicting organ transplant rejection. In particular, the present invention relates to the detection and prediction of kidney transplant rejection by detection of CXCR3 and CCL chemokines in urine. The present invention provides improved methods of diagnosing organ rejection and determining the efficacy of anti-rejection drugs.

Abstract: The present invention relates to methods of diagnosing, predicting and monitoring kidney disorders. In particular, the present invention relates to the diagnosis, prediction and monitoring of kidney disorders by detection of cytokines, cytokine-related compounds and chemokines in urine. The present invention further relates to methods and compositions for assessing the efficacy of agents and interventions used to treat kidney disorders.

Abstract: The present invention relates to methods of diagnosing, predicting and monitoring kidney disorders. In particular, the present invention relates to the diagnosis, prediction and monitoring of contrast-induced nephropathy by detection of cytokines, cytokine-related compounds, and chemokines in urine. The present invention further relates to methods and compositions for assessing the efficacy of agents and interventions used to treat contrast-induce nephropathy.

Abstract: The present invention relates to methods of diagnosing, predicting and monitoring kidney disorders. In particular, the present invention relates to the diagnosis, prediction and monitoring of kidney disorders by detection of cytokines, cytokine-related compounds and chemokines in urine. The present invention further relates to methods and compositions for assessing the efficacy of agents and interventions used to treat kidney disorders.

Abstract: The present invention is related to transplant rejection. In particular, the present invention relates to determining the functional status of alloreactive T cells and correlating the functional status to in vivo immune responses (e.g., tolerance, rejection, or absence of rejection mediated by T cells). The present invention finds use in basic research, clinical (e.g., transplant) and therapeutic settings.

Abstract: The present invention relates to methods of diagnosing, predicting and monitoring conditions and disorders associated organ transplantation and organ health. In particular, the present invention relates to the diagnosis, prediction and monitoring of disorders, conditions, and organ status by detection of cytokines, cytokine-related compounds, and chemokines, particularly in urine. The present invention further relates to methods and compositions for assessing the efficacy of agents and interventions used to treat organ associated disorders and conditions and for maintaining organ health.

Abstract: The present invention relates to methods and kits for the diagnosis and monitoring of hepatitis C virus (HCV) infection and/or Kaposi's sarcoma herpesvirus infection (KSHV) in a subject, as well as other infectious diseases and agents. In particular, the present invention relates to the diagnosis and monitoring of infectious disease through the use of multiple agents directed at a target of interest. For example, the present invention provides for the detection of HCV infection by the detection of antibodies to HCV C22 core, NS 4 (C-10003), NS3 and NS5 antigens, and/or to the diagnosis and monitoring of KSHV infection by detection of antibodies to K8.1, orf73/LNA1 and orf65 antigens in serum. The present invention further relates to methods and kits for assessing the efficacy of agents and interventions used to treat infectious diseases.

Abstract: The present invention relates to methods of diagnosing, predicting and monitoring kidney disorders. In particular, the present invention relates to the diagnosis, prediction and monitoring of kidney disorders by detection of cytokines, cytokine-related compounds and chemokines in urine. The present invention further relates to methods and compositions for assessing the efficacy of agents and interventions used to treat kidney disorders.

Abstract: The present invention relates to methods of diagnosing, predicting and monitoring kidney diseases, including acute renal failure, renal tubular interstitial disease and glomerulonephritis. In particular, the present invention relates to the detection, prediction and monitoring of kidney diseases by detection of CXCR3 and CCL chemokines in urine. The present invention further relates to methods and compositions for assessing the efficacy of agents and interventions used to treat kidney diseases.

Abstract: The present invention provides compositions and methods for detecting analytes in urine. In particular, the present invention provides reagents for accurately detecting antigens in urine through the use of antibody-based assays.

Abstract: The present invention relates to compositions and methods for conducting cell division and proliferation assays (e.g., using flow cytometry), and in particular, to improvements in the effective storage and handling of dyes and reagents used therein.